Orforglipron: The New Oral GLP-1 Agonist

Video will be live on Monday, June 24 at 1:00 PM Central Time. 

▪️ Join my channel to get access to perks! 
▪️ Download my FREE 7-Day Best Weight Journal here.  
▪️ Subscribe to my YouTube channel here.   

I have great news for those who dislike needles or prefer a daily reminder to engage in positive behaviors. There’s a new oral GLP-1 molecule making its way to market called Orforglipron!

Currently, Rybelsus is the only oral GLP-1 available, approved for diabetes management up to a dose of 14mg once daily. Rybelsus contains semaglutide, found in Ozempic and Wegovy, but it’s not yet approved for weight management. Trials with 50mg once daily have shown results similar to injectable Wegovy, with a 15% weight loss from baseline. However, Rybelsus needs to be taken on an empty stomach, at least 30 minutes before food or other medications—a bit inconvenient.

Orforglipron, on the other hand, is a game-changer. It’s an oral nonpeptide GLP-1 receptor agonist that can be taken without regard to food, drink, or other medications. It’s designed to be absorbed easily through the digestive tract, without needing an absorption enhancer like Rybelsus. This makes it much more convenient for daily use.

So, how effective is Orforglipron? 

Let’s dive into the Phase 2 RCT study. This preliminary trial involved 272 participants with obesity, split into groups receiving either 12mg, 24mg, 36mg, or 48mg of Orforglipron daily, or a placebo. Participants received basic counseling on healthy eating and exercise.

The study found that participants, who were mostly female with an average age of 54, weight of 108.7kg, and BMI of 37.9, saw impressive results. Those on 45mg daily of Orforglipron lost 14.7% of their baseline weight after 36 weeks, and the weight loss trend hadn’t plateaued yet. For reference, this is comparable to results from the OASIS Trial with oral semaglutide at 50mg daily, which led to a 15.1% weight loss after 68 weeks.

Safety-wise, the side effects were typical for GLP-1 receptor agonists: nausea, vomiting, diarrhea, and constipation. Nothing out of the ordinary here.

Orforglipron is a promising new oral GLP-1 RA that might offer a more convenient and potentially more effective option for weight management. Its smaller molecule size might also mean a cheaper alternative, though time will tell. Plus, more options could help alleviate current drug shortages—exciting times ahead!

Remember, small tweaks lead to massive peaks. Thanks for watching and I’ll catch you next week! 

Don’t forget to hit the subscribe button for more insightful content, and consider joining our YouTube Members Membership for exclusive benefits and monthly live sessions. 

Watch my previous videos to learn how to fight obesity and about the best medicine for weight loss: 
▪️ Watch This Before Taking Mounjaro  
▪️ From Ozempic to Mounjaro 
▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro 
▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!  
▪️ Ozempic: Stomach Paralysis Update  
▪️ How to Switch from Ozempic (or Wegovy) to Mounjaro  
▪️ Ozempic Paralyzed My Stomach 
▪️ How to Inject Mounjaro: step-by-step tutorial

Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy – http://apothecarerx.ca 

Products I recommend to support your weight-loss journey: 
▪️ Managing Constipation 
▪️ Managing Diarrhea 
▪️ Managing Heartburn 
▪️ Internalized Weight Bias 
▪️ Protein Bars
▪️ Scales and More 
▪️ Supplements 
▪️ Activity Trackers  
▪️ My favorite Books 

– 

Dr. Dan

Follow me on social media for regular updates – @TheOfficialDrDan

Subscribe to my newsletter for a heads-up on all new content.

Sharing is caring! Here’s the social, email, and even text link –
https://healthevolved.co/orforglipron

If you need some coaching support on your weight management journey, you can book a consultation with me to see if you’d be a good fit for our program. 

Questions or comments? Please send them my way on our Contact Us page!

Share:

More Posts

Orforglipron: A Diabetes Game Changer Hidden in Plain Sight

Orforglipron is a once-daily oral GLP-1 medication showing powerful results for people with type 2 diabetes. It lowers A1C and supports significant weight loss—all without injections, food restrictions, or lifestyle coaching. Based on the ACHIEVE-1 trial, this treatment could change how early type 2 diabetes is managed.

Peripheral Artery Disease (PAD) & Semglutide

If walking causes burning or cramping in your legs, it could be more than just aging or being out of shape—it might be Peripheral Artery Disease (PAD). Learn how semaglutide, commonly known for weight loss and diabetes, is now showing promise in improving mobility and reducing leg pain by improving blood flow.

CagriSema vs Tirzepatide

CagriSema and Tirzepatide are two of the most talked-about names in obesity treatment—now see how they compare. Explore the latest clinical results, real-world impacts, and what sets each medication apart when it comes to weight loss and metabolic health.

Mazdutide: China’s GLP-1 Gamechanger

Mazdutide is a new GLP-1/glucagon receptor agonist from China, showing promising weight loss results in recent trials. With up to 14% reduction in a lower-BMI population, it raises key questions about how it compares to Wegovy, Zepbound, and the future of obesity treatment.

Send Us A Message

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.